Lianhuan Pharmaceutical: Holding subsidiary Chang Le Pharmaceutical obtains Drug Registration Certificate for Amlodipine and Losartan Tablets

Lian Huan Pharmaceutical announced that its controlling subsidiary, Changle Pharmaceutical, has received the "Drug Registration Certificate" issued by the National Medical Products Administration for the valsartan potassium tablets. This drug is used to treat primary hypertension in adults, with Changle Pharmaceutical investing approximately RMB 10.99 million in the research and development of valsartan potassium tablets. As of the announcement date, Changle Pharmaceutical has obtained 10 production approvals. The issuance of the "Drug Registration Certificate" is not expected to have a significant impact on the company's recent business performance.